Skip to main content
. 2013 Jan 7;8:9. doi: 10.1186/1748-717X-8-9

Table 1.

Patient characteristics (as treated)

 
 TARGIT-A
  
 EBRT+boost
  
 
 IORT (n = 25)
 EBRT (n = 46)
 IORT-EBRT (n = 16)
  
 IORT-boost (n=90)
 EBRT-boost (n=53)
  
  No. % No. % No. % P * No. % No. % P **
Age, years
  
  
  
  
  
  
  
  
  
  
  
  
 Mean
 65.5
 65.2
 61.8
 0.276
 60.1
 49.9
 <0.001
 SD
 8.5
 8.2
 6.0
  
 11.1
 9.2
  
Married/partnered
 14
 58
 22
 48
 13
 81
 0.066
 58
 64
 39
 76
 0.191
Employed
 4
 16
 9
 20
 0
 0
 0.185
 27
 31
 31
 60
 <0.001
Months since BCS
  
  
  
  
  
  
  
  
  
  
  
  
 Mean
 32.7
 30.6
 35.6
 0.641
 34.2
 47.5
 <0.001
 SD
 19.1
 17.2
 19.6
  
 13.7
 7.4
  
Tumor size
  
  
  
  
  
  
  
  
  
  
  
  
 0-1 cm
 8
 32
 14
 30
 3
 19
 0.376
 13
 14
 6
 11
 0.414
 1-2 cm
 16
 64
 25
 34
 9
 56
  
 49
 54
 23
 43
  
 > 2 cm
 1
 4
 7
 15
 4
 25
  
 28
 31
 24
 45
  
Nodal involvement
  
  
  
  
  
  
  
  
  
  
  
  
 N0
 23
 92
 36
 78
 14
 88
 0.622
 66
 73
 34
 65a
 0.253
 N1
 2
 9
 9
 20
 2
 12
  
 20
 22
 11
 21
  
 > N1
 0
 0
 1
 2
 0
 0
  
 4
 4
 7
 13
  
ALND
 4
 16
 14
 30
 4
 25
 0.409
 55
 61
 41
 79a
 <0.001
Chemotherapy
 4
 17
 5
 11
 2
 12
 0.908
 18
 20
 36
 68
 <0.001
Endocrine therapy
 23
 96
 40
 93
 13
 81
 0.322
 70
 78
 36
 86
 0.349
Radiotherapy of supra- and infraclavicular nodes
 0
 0
 2
 4
 0
 0
 0.693
 7
 8
 10
 19
 0.049
Medical comorbidities ≥2b 14 56 37 80 11 69 0.091 49 54 9 17 <0.001

Abbreviations: TARGIT-A, TARGeted Intra-operative radioTherapy versus whole breast radiotherapy for breast cancer, IORT, intraoperative radiotherapy, EBRT, external beam whole breast radiotherapy, ALND, axillary lymph node dissection.

* IORT versus EBRT versus IORT-EBRT.

** IORT-EBRT versus IORT-boost versus EBRT-boost.

a One patient without axillary assessment.

b Coexisting medical conditions were assessed by medical record review and by patient self-report. A medical comorbidity was defined as having two or more physical illnesses or injuries that needed long-term treatment.